COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials -
COMMUNIQUÉ DE PRESSE
Ivanhoe Electric and Ma'aden Joint Venture Commences Drilling Activities in Saudi Arabia
Ivanhoe Electric Inc. and Ma'aden Joint Venture to commence drilling in Saudi Arabia following Typhoon™ anomaly detection in Al Amar Belt. Exploration activities expanding into Bir Umq, Wadi Bidah and platform license applications -
COMMUNIQUÉ DE PRESSE
The Penco Module Advances to the Next Stage of Its Permitting Process
Aclara Resources Inc. announces progress in the evaluation process of Penco Module's Environmental Impact Assessment, with reduced observations received and commitment to sustainable rare earth extraction practices -
COMMUNIQUÉ DE PRESSE
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing -
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected
